Shalom E Kelman. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Angiogenesis Inhibitors/administration & dosageAnimalsAnti-Inflammatory Agents/administration & dosageAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal, HumanizedBevacizumabDisease Models, AnimalHumansInjectionsOphthalmologic Surgical Procedures/adverse effectsOptic Nerve/drug effectsOptic Nerve/physiopathologyOptic Neuritis/drug therapyOptic Neuritis/physiopathologyOptic Neuritis/prevention & controlOptic Neuropathy, Ischemic/drug therapyOptic Neuropathy, Ischemic/physiopathologyOptic Neuropathy, Ischemic/surgeryPapilledema/drug therapyPapilledema/physiopathologyPapilledema/prevention & controlPilot ProjectsTreatment OutcomeTriamcinolone/administration & dosageVitreous Body/drug effects
Substances: See more » Angiogenesis InhibitorsAnti-Inflammatory AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedTriamcinoloneBevacizumab
Year: 2007 PMID: 17895813 DOI: 10.1097/WNO.0b013e31814a61ae
Source DB: PubMed Journal: J Neuroophthalmol ISSN: 1070-8022 Impact factor: 3.042